28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Peking Union Medical College
Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
Peking Union Medical College
Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Metabasis Therapeutics
Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase.
F. Hoffmann-La Roche
Designing inhibitors against fructose 1,6-bisphosphatase: exploring natural products for novel inhibitor scaffolds.
Boston College
Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors.
Daiichi Sankyo
Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
F. Hoffmann-La Roche
Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Metabasis Therapeutics
Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors.
Daiichi Sankyo
A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase.
Boston College
Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics.
Metabasis Therapeutics
Novel heteroaromatic organofluorine inhibitors of fructose-1,6-bisphosphatase.
University of Massachusetts
Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites.
F. Hoffmann-La Roche
Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.
University Institute of Pharmaceutical Sciences
Current anti-diabetic agents and their molecular targets: A review.
University of Kwazulu-Natal
Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase.
Abbott Laboratories
-Acylamino Saccharin as an Emerging Cysteine-Directed Covalent Warhead and Its Application in the Identification of Novel FBPase Inhibitors toward Glucose Reduction.
Central China Normal University
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.
Pfizer
Biological evaluation and SAR analysis of novel covalent inhibitors against fructose-1,6-bisphosphatase.
Anhui University of Technology
Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography.
Pfizer
Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
East China University of Science and Technology
Structural Specificity of Flavonoids in the Inhibition of Human Fructose 1,6-Bisphosphatase.
University of Porto
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.
Central China Normal University